Durable Remission of Sézary Syndrome after Unrelated Bone Marrow Transplantation by Reduced-Intensity Conditioning

Kahata, Kaoru; Hashino, Satoshi; Takahata, Mutsumi; Fujisawa, Fumie; Kondo, Takeshi; Kobayashi, Shogo; Fujita, Yasuyuki; Shimizu, Hiroshi; Imamura, Masahiro; Asaka, Masahiro

doi:10.1159/000151510

Cited by 13 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Twenty of the 22 patients received a reduced-intensity (nonmyeloablative) regimen (Table IV). [311][312][313][314][316][317][318][319] Overall outcome results are encouraging. Of the 22 SS allogeneic HSCT recipients reviewed, 15 patients were alive and disease free at a mean posttransplantation follow-up of 44 months (range 18-109 months).…”

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 94%

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

154

135

View full text Add to dashboard Cite

Section: Hematopoietic Stem Cell Transplantationmentioning

confidence: 94%

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Olsen

Rook

Zic

et al. 2011

Journal of the American Academy of Dermatology

154

135

View full text Add to dashboard Cite

“…Aksine allojenik kök hücre nakli MF hastalarında greftversus-lenfoma etkisi aracılığıyla uzun süreli remisyon sağlayabilir. Tedaviye bağlı mortalite yaklaşık %30 olduğundan, miyeloablatif olmayan (mini) allojenik kök hücre nakli azaltılmış toksisite ve greft-versus-lenfoma etkisiyle, olası bir tedavi alternatifi olabilir (74).…”

Section: Hematopoetik Kök Hücre Transplantasyonuunclassified

Mikozis Fungoides Güncel

2016

Dermatoz

View full text Add to dashboard Cite

Özet Mikozis Fungoides GüncelDerinin primer T hücreli lenfomaları, ekstranodal non-Hodgkin lenfomaların heterojen bir grubudur. Mikozis fungoides ve Sezary sendromu, kutanöz T hücreli lenfomalarınen sık iki alt tipidir. Hastalık, yamadan tümör formuna ilerleyici yavaş bir seyir gösterir. İleri evrelerde lenf nodlarında ve iç organlarda tutulum olabilir veya hastalık yüksek dereceli bir lenfoma türüne dönü-şebilir. Tanı klinik, histopatolojik ve immünolojik verilerin kombinasyonuna dayanır. Hastalığı evrelemek için TNM sistemi kullanılmaktadır. Sınırlı evre hastalığı olanlar, deriye yönelik tedavilerle etkin bir şekilde tedavi edilebilir. Bu tedaviler; topikal kortikosteroidler, topikal nitrojen mustard, topikal beksaroten, lokal radyoterapi ve topikal PUVA tedavisini içermektedir. Eğer deriye yönelik tedaviler etkisiz ise veya ileri evre hastalık gelişirse; interferon alfa, sistemik beksaroten, fotoferez, denilökin diftitoks, vorinostat, alemtuzumab, sitotoksik kemoterapi veya kombinasyonları içeren sistemik tedavilere başlanır. Mikozis fungoidesin prognozu, hastalığın evresine, lezyonların boyutu ve tipine, ekstrakutanöz hastalık varlığına bağlıdır. Anahtar Kelimeler: Kutanöz T hücreli lenfoma, Mikozis fungoides, Sezary sendromu Abstract Mycosis Fungoides up-to-DatePrimary cutaneous T-cell lymphomas are a heterogeneous group of extranodal non-Hodgkin's lymphomas. Mycosis fungoides and Sezary syndrome are the two most common subtypes of cutaneous T-cell lymphomas. Disease shows a slow progression from patch to tumor form. In advanced stages, lymph nodes and internal organs can be involved, or disease may be converted to a high-grade lymphoma. Clinical diagnosis is based on the combination of histological and immunological data. The TNM system is used to stage the disease. Limited-stage disease can be treated effectively with skin-directed treatments. These treatments include; topical corticosteroids, topical nitrogen mustard, topical bexarotene comprises radiotherapy, and local PUVA. If skin-directed treatments are ineffective or advanced stage disease develops; systemic therapies including interferon alpha, systemic bexarotene, photopheresis, denileukin diftitox, vorinostat, alemtuzumab, cytotoxic chemotherapy or combinations thereof must be started. Mycosis fungoides prognosis is due to the stage of the disease, lesion size and type, and presence of extracutaneous disease.Keywords: Cutaneous T-Cell lymphoma, Mycosis fungoides, Sezary syndrome Sayfa 1/9 Mikozis Fungoides Güncelhttp://www.dermatoz.org/2016/1/dermatoz16071d1.pdf doi: 10.15624.dermatoz16071d1 GirişDerinin primer T hücreli lenfomaları, büyük ölçüde tanı anında deriye sınırlı olan, ekstranodal nonHodgkin lenfomaların heterojen bir grubudur (1). Mikozis fungoides (MF)ve Sezary sendromu (SS) , kutanöz T hücreli lenfomaların yaklaşık yarısını oluşturan, en sık iki alt tiptir (2). Mikozis fungoides, epidermotropik CD4+ T hücrelerinin monoklonal çoğalmasıyla karakterize; derinin T hücreli lenfomalarının en sık görülen formudur (1, 3, 4).Sezarysendromu kö...

show abstract

“…The complete remission rate lasting for up to six years was 58 % . Since the treatment‐related mortality is approximately 30 %, the non‐myeloablative (mini) allogeneic stem cell transplantation can represent a possible therapeutic alternative, achieving a graft‐versus‐lymphoma effect with reduced therapeutic toxicity .…”

Section: Systemic Therapiesmentioning

confidence: 99%

New and established treatment options for mycosis fungoides and Sézary syndrome – an update

Dugas-Breit¹,

Schulze²,

Hallermann³

2014

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary At the time of diagnosis primary cutaneous lymphomas are limited to the skin. T‐cell lymphomas represent at least two thirds of all primary cutaneous lymphomas with mycosis fungoides and Sézary syndrome being the most frequent entities. A precise staging based on clinical, histological, immunohistological and molecular biological criteria is crucial for selecting the appropriate therapy. Since curative treatment is only possible in exceptional cases, the aim of any therapy is to achieve healing of the skin lesions, minimizing relapses, preventing progression and maintaining the quality of life. While in early disease stages skin‐directed therapy is being used, in later stages systemic treatments become more important. This work aims to provide an overview of established and new therapies for the treatment of mycosis fungoides and Sézary syndrome.

show abstract

Durable Remission of Sézary Syndrome after Unrelated Bone Marrow Transplantation by Reduced-Intensity Conditioning

Cited by 13 publications

References 51 publications

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Mikozis Fungoides Güncel

New and established treatment options for mycosis fungoides and Sézary syndrome – an update

Contact Info

Product

Resources

About